Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 14, 2022; 28(34): 4959-4972
Published online Sep 14, 2022. doi: 10.3748/wjg.v28.i34.4959
Published online Sep 14, 2022. doi: 10.3748/wjg.v28.i34.4959
Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy
Masahiro Iizuka, Shiho Sagara, Akita Health Care Center, Akita Red Cross Hospital, Akita 010-0001, Japan
Masahiro Iizuka, Takeshi Etou, Department of Gastroenterology, Akita Red Cross Hospital, Akita 010-1495, Japan
Author contributions: Iizuka M was responsible for the conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version; Etou T and Sagara S was responsible for the critical revision and final approval of the final version.
Conflict-of-interest statement: There is no conflicts of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Masahiro Iizuka, MD, PhD, Director, Doctor, Akita Health Care Center, Akita Red Cross Hospital, 3-4-23 Nakadori, Akita 010-0001, Japan.
Received: May 30, 2022
Peer-review started: May 30, 2022
First decision: June 18, 2022
Revised: July 16, 2022
Accepted: August 16, 2022
Article in press: August 16, 2022
Published online: September 14, 2022
Processing time: 99 Days and 19.4 Hours
Peer-review started: May 30, 2022
First decision: June 18, 2022
Revised: July 16, 2022
Accepted: August 16, 2022
Article in press: August 16, 2022
Published online: September 14, 2022
Processing time: 99 Days and 19.4 Hours
Core Tip
Core Tip: Management of refractory ulcerative colitis (UC) experiencing primary non-response or loss of response to biologics is a critical issue. We first summarized the efficacy of cytapheresis (CAP) for such patients. Although CAP tended to have lower effects for induction of remission in patients with UC who were refractory to biologics, combination therapies with CAP and biologics induced clinical remission or response in more than 40% of such patients with UC on average. Given the excellent safety profile of CAP, we believe that this combination therapy can be an alternative therapeutic strategy for such refractory UC patients.